FIRMAGON is a prescription medication primarily used in the treatment of advanced prostate cancer. Its active ingredient, degarelix, belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) receptor antagonists. By directly targeting and blocking GnRH receptors in the pituitary gland, FIRMAGON effectively reduces the production of testosterone, a hormone that can promote the growth of prostate cancer cells. Unlike some other hormone therapies that initially cause a surge in testosterone levels before decreasing them, FIRMAGON rapidly lowers testosterone levels without this initial surge, providing a quick response in the management of prostate cancer symptoms. It is administered through subcutaneous injection, typically by a healthcare professional, and its dosage and frequency depend on the specifics of the patient's condition and response to treatment.